SIGILON THERAPEUTICS

Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

SIGILON THERAPEUTICS

Social Links:

Facebook

Linkedin

Twitter

X

Industry:

Biotechnology

Founded:

2015-01-01

Address:

Cambridge, Massachusetts, United States

Country:

United States

Website Url:

http://www.sigilon.com

Total Employee:

51+

Status:

Active

Contact:

617-336-7540

Email Addresses:

[email protected]

Total Funding:

263.2 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager WordPress Font Awesome Apache Wordpress Plugins Sitelinks Search Box

Similar Organizations

d2g-oncology-logo

D2G Oncology

D2G Oncology is a biotechnology company that specializes in relating drugs to genotypes to transform precision cancer therapeutics.

Current Advisors List

stephen-oesterle_image

Stephen Oesterle Board Director @ Sigilon Therapeutics
Board_member
2016-01-01

Current Employees Featured

rogerio-vivaldi_image

Rogerio Vivaldi
Rogerio Vivaldi President, CEO @ Sigilon Therapeutics
President, CEO
2018-08-01

daniel-anderson_image

Daniel Anderson
Daniel Anderson Co-Founder @ Sigilon Therapeutics
Co-Founder

josé-oberholzer_image

José Oberholzer
José Oberholzer Co-Founder @ Sigilon Therapeutics
Co-Founder

arturo-vegas_image

Arturo Vegas
Arturo Vegas Co-Founder @ Sigilon Therapeutics
Co-Founder

philip-ashton-rickardt_image

Philip Ashton-Rickardt
Philip Ashton-Rickardt Chief Scientific Officer @ Sigilon Therapeutics
Chief Scientific Officer
2021-06-01

susan-drapeau_image

Susan Drapeau
Susan Drapeau Chief Preclinical Operations Officer @ Sigilon Therapeutics
Chief Preclinical Operations Officer
2021-09-01

may-orfali_image

May Orfali
May Orfali EVP and CMO @ Sigilon Therapeutics
EVP and CMO
2021-11-01

david-peritt_image

David Peritt
David Peritt Chief Technology Officer @ Sigilon Therapeutics
Chief Technology Officer
2017-05-01

michael-owings_image

Michael Owings
Michael Owings Head Of Quality @ Sigilon Therapeutics
Head Of Quality
2019-04-01

matt-kowalsky_image

Matt Kowalsky
Matt Kowalsky Chief Legal Officer @ Sigilon Therapeutics
Chief Legal Officer
2020-10-01

Founder

arturo-vegas_image

Arturo Vegas

daniel-anderson_image

Daniel Anderson

josé-oberholzer_image

José Oberholzer

omid-veiseh_image

Omid Veiseh

robert-langer_image

Robert Langer

Stock Details

Company's stock symbol is NASDAQ:SGTX

Investors List

eli-lilly_image

Eli Lilly

Eli Lilly investment in Series B - Sigilon Therapeutics

longevity-vision-fund_image

Longevity Vision Fund

Longevity Vision Fund investment in Series B - Sigilon Therapeutics

blackrock_image

BlackRock

BlackRock investment in Series B - Sigilon Therapeutics

flagship-ventures_image

Flagship Pioneering

Flagship Pioneering investment in Series B - Sigilon Therapeutics

canada-pension-plan-investment-board_image

Canada Pension Plan Investment Board

Canada Pension Plan Investment Board investment in Series B - Sigilon Therapeutics

eli-lilly_image

Eli Lilly

Eli Lilly investment in Series A - Sigilon Therapeutics

Key Employee Changes

Date	New article
2021-07-19	Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

Official Site Inspections

http://www.sigilon.com Semrush global rank: 10.15 M Semrush visits lastest month: 39

Host Informations
Whois Informations

Loading ...

More informations about "Sigilon Therapeutics" on Search Engine